Table 2.
Summary of efficacy end points in the current study
| Treatment | N | Mean number of recurrences per year | Time to first recurrencea (days) | % recurrence-free | % with decrease in recurrence | % with >50% reduction |
|---|---|---|---|---|---|---|
| No-treatment control | 20 | 5.5 | 105.01 | 0.0% | – | – |
| Pretreatment control | 119 | 7.27 (3.2b) | 103.91 | 0.0% | 90.8% | 73.1% |
| Treatment | 119 | 2.39 (5.7b) (P<0.0001, pretreatment) (P<0.001, no treatment) | 537.34 (P<0.0001, both controls) | 42.0% (P<0.0001, both controls) |
Notes: The participants had at least one genital herpes recurrence per year.
a
Using Kaplan–Meier.
b
Results from the two questions testing internal consistency (P<0.0001).